WALTHAM,
Mass., Aug. 29, 2024 /PRNewswire/ -- Q32 Bio Inc.
(Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company
focused on developing biologic therapeutics to restore immune
homeostasis, today announced that management will participate in
three upcoming investor conferences in September:
Morgan Stanley 22nd Annual Global Healthcare
Conference
Date: Thursday, September
5, 2024
Location: New York, NY
2024 Cantor Fitzgerald Global Healthcare
Conference
Date: Tuesday, September
17, 2024
Presentation Time: 3:40 p.m. E.T.
Location: New York, NY
Stifel 2024 Virtual Immunology and Inflammation
Summit
Date: Wednesday, September 18,
2024
Presentation Time: 11:30 a.m.
E.T.
Location: Virtual
A webcast of the Cantor and Stifel presentations will be
available on the Events and Presentations page of Q32 Bio's website
at www.q32bio.com. Archived replays will be available for 30 days
following the event.
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company developing
biologic therapeutics targeting potent regulators of the innate and
adaptive immune systems to re-balance immunity in autoimmune and
inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7
/ TSLP receptor pathways and complement system, address immune
dysregulation to help patients take back control of their
lives.
Q32 Bio's program for adaptive immunity, bempikibart (ADX-914),
is a fully human anti-IL-7Rα antibody that re-regulates adaptive
immune function for the treatment of autoimmune diseases. It is
being evaluated in two Phase 2 trials for the treatment of atopic
dermatitis and alopecia areata. The IL-7 and TSLP pathways have
been genetically and biologically implicated in driving several T
cell-mediated pathological processes in numerous autoimmune
diseases. Q32 Bio's program for innate immunity, ADX-097, is based
on a novel platform enabling tissue-targeted regulation of the
complement system without long-term systemic blockade – a key
differentiator versus current complement therapeutics. Q32 Bio has
completed a first-in-human, Phase 1 ascending dose clinical study
of ADX-097 in healthy volunteers.
For more information, visit www.Q32Bio.com.
Availability of Other Information About Q32 Bio
Investors and others should note that we communicate with our
investors and the public using our company
website www.Q32Bio.com, including, but not limited to, company
disclosures, investor presentations and FAQs, Securities and
Exchange Commission filings, press releases, public conference
call transcripts and webcast transcripts, as well as on X (formerly
Twitter) and LinkedIn. The information that we post on our website
or on X or LinkedIn could be deemed to be material information. As
a result, we encourage investors, the media and others interested
to review the information that we post there on a regular basis.
The contents of our website or social media shall not be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended.
Contacts:
Investors: Brendan
Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
Q32Bio@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-upcoming-september-investor-conferences-302233260.html
SOURCE Q32 Bio